Merck

@Merck • 216,716 subscribers

We aspire to be the premier research-intensive biopharmaceutical company. Intended for U.S. residents only. FLS: https://t.co/QUXfCXVlx3

Shorts

In collaboration with Moderna, we’re excited to share the first positive Phase 3 topline results for our investigational individualized neoantigen therapy (INT) in combination with our company’s immunotherapy in the adjuvant setting for certain patients with completely resected stage IIB-IV #melanoma:

In collaboration with Moderna, we’re excited to share the first positive Phase 3 topline results for our investigational individualized neoantigen therapy (INT) in combination with our company’s immunotherapy in the adjuvant setting for certain patients with completely resected stage IIB-IV #melanoma:

39,935 görüntüleme

Every day, our scientists tackle challenging problems like the scalable synthesis of complex molecules. In this latest publication in Science Magazine, we share how we’re using #biocatalysis to manufacture orally available macrocyclic peptides. Learn more:

Every day, our scientists tackle challenging problems like the scalable synthesis of complex molecules. In this latest publication in Science Magazine, we share how we’re using #biocatalysis to manufacture orally available macrocyclic peptides. Learn more:

13,959 görüntüleme

Join us today at 9 a.m. ET to learn more about our Q1 2026 #earnings: $MRK

Join us today at 9 a.m. ET to learn more about our Q1 2026 #earnings: $MRK

12,201 görüntüleme

Videos

Anya Rossi

sweetdream.ai

SweetDream.ai•Sponsored•Livecam

Watch Anya Live

Anya is streaming live right now! Join her private show and enjoy exclusive content.

Exclusive private shows

1.2k viewers online

Private Show

Join now for exclusive access

Free preview available • Premium content

We believe great medicines start with great conversations.

We believe great medicines start with great conversations.

134,749,066 görüntüleme • 5 ay önce

Our One Pipeline strategy enables us to advance bold science, whether it comes from our own labs or from our collaborator’s labs.

Our One Pipeline strategy enables us to advance bold science, whether it comes from our own labs or from our collaborator’s labs.

77,444,157 görüntüleme • 5 ay önce

With our broad set of global resources, we work alongside our partners to move bold science forward.

With our broad set of global resources, we work alongside our partners to move bold science forward.

70,903,190 görüntüleme • 5 ay önce

Our business development and licensing team looks for opportunities to complement and augment our pipeline where science and value align.

Our business development and licensing team looks for opportunities to complement and augment our pipeline where science and value align.

53,274,782 görüntüleme • 5 ay önce

We believe great medicines start with great conversations.

We believe great medicines start with great conversations.

18,362,169 görüntüleme • 5 ay önce

Our business development and licensing team looks for opportunities to complement and augment our pipeline where science and value align.

Our business development and licensing team looks for opportunities to complement and augment our pipeline where science and value align.

15,363,911 görüntüleme • 5 ay önce

With our broad set of global resources, we work alongside our partners to move bold science forward.

With our broad set of global resources, we work alongside our partners to move bold science forward.

17,894,170 görüntüleme • 5 ay önce

Our One Pipeline strategy enables us to advance bold science, whether it comes from our own labs or from our collaborator’s labs.

Our One Pipeline strategy enables us to advance bold science, whether it comes from our own labs or from our collaborator’s labs.

17,031,804 görüntüleme • 5 ay önce

Helping to address barriers to cancer screenings and care, reducing disparities and expanding access are just some of the ways we work every day to shape the outcomes for people with cancer.

Helping to address barriers to cancer screenings and care, reducing disparities and expanding access are just some of the ways we work every day to shape the outcomes for people with cancer.

40,540,508 görüntüleme • 1 yıl önce

People with cancer deserve more – that’s what drives every new pathway and technology we investigate and every partnership we pursue. Our research focuses on exploring novel approaches to help patients fight cancer.

People with cancer deserve more – that’s what drives every new pathway and technology we investigate and every partnership we pursue. Our research focuses on exploring novel approaches to help patients fight cancer.

40,420,329 görüntüleme • 1 yıl önce

Our scientists are advancing the largest pipeline in our company’s history. And the numbers speak for themselves — take a look at our science in action.

Our scientists are advancing the largest pipeline in our company’s history. And the numbers speak for themselves — take a look at our science in action.

3,016,553 görüntüleme • 1 yıl önce

It can take up to 10 years for a single molecule to become a medicine. But where does the process even begin? From discovery to distribution, follow the steps in the journey of a molecule to find out.

It can take up to 10 years for a single molecule to become a medicine. But where does the process even begin? From discovery to distribution, follow the steps in the journey of a molecule to find out.

2,198,337 görüntüleme • 1 yıl önce

Today we announced our initial post-approval access plans for our investigational HIV pre-exposure prophylaxis (PrEP). We are accelerating our access planning to help ensure that, if approved by the regulatory agency, this HIV prevention option can quickly reach those who need it in low- and middle-income countries. Learn more:

Today we announced our initial post-approval access plans for our investigational HIV pre-exposure prophylaxis (PrEP). We are accelerating our access planning to help ensure that, if approved by the regulatory agency, this HIV prevention option can quickly reach those who need it in low- and middle-income countries. Learn more:

14,800 görüntüleme • 2 ay önce

Today at #ASCO26, in collaboration with Moderna, we're proud to present five-year follow-up results from a Phase 2b study evaluating our investigational individualized neoantigen therapy for #melanoma. Learn more:

Today at #ASCO26, in collaboration with Moderna, we're proud to present five-year follow-up results from a Phase 2b study evaluating our investigational individualized neoantigen therapy for #melanoma. Learn more:

14,181 görüntüleme • 3 ay önce

We’re presenting new data at #ASCO26 from our robust oncology portfolio and pipeline across earlier-stage and advanced tumor types. We’re focused on advancing research to fight cancer and evaluate new approaches to help prolong and protect lives. Learn more:

We’re presenting new data at #ASCO26 from our robust oncology portfolio and pipeline across earlier-stage and advanced tumor types. We’re focused on advancing research to fight cancer and evaluate new approaches to help prolong and protect lives. Learn more:

15,745 görüntüleme • 4 ay önce

Today we announced the initiation of a pivotal Phase 2b/3 trial for the treatment of patients with neovascular age-related macular degeneration (#wetAMD). Learn more: #ophthalmology

Today we announced the initiation of a pivotal Phase 2b/3 trial for the treatment of patients with neovascular age-related macular degeneration (#wetAMD). Learn more: #ophthalmology

16,982 görüntüleme • 5 ay önce

Today, Merck completed the acquisition of Terns Pharmaceuticals, further strengthening our #oncology portfolio and reinforcing our focus on science‑driven innovation. Learn more:

Today, Merck completed the acquisition of Terns Pharmaceuticals, further strengthening our #oncology portfolio and reinforcing our focus on science‑driven innovation. Learn more:

10,371 görüntüleme • 4 ay önce

We’re proud to partner with Google Cloud to help shape the future of biopharmaceutical innovation with AI-enabled enterprise transformation. This collaboration is about unlocking new value: accelerating discovery, modernizing how we work and empowering our teams to focus on the highest-impact science and solutions for patients. Learn more about the landmark partnership:

We’re proud to partner with Google Cloud to help shape the future of biopharmaceutical innovation with AI-enabled enterprise transformation. This collaboration is about unlocking new value: accelerating discovery, modernizing how we work and empowering our teams to focus on the highest-impact science and solutions for patients. Learn more about the landmark partnership:

10,157 görüntüleme • 5 ay önce